HT-0712

HT-0712
Clinical data
Other names	HT-0712, IPL 455,903
ATC code	None;
Identifiers
	IUPAC name (3S,5S)-5-(3-(Cyclopentyloxy)-4-methoxyphenyl)-3-(3-methylbenzyl)piperidin-2-one;
CAS Number	617720-02-2;
PubChem CID	9865375;
ChemSpider	8041067 ;
UNII	2O43FXG9IG;
CompTox Dashboard (EPA)	DTXSID70893926 ;
Chemical and physical data
Formula	C25H31NO3
Molar mass	393.527 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C3NC[C@H](c2cc(OC1CCCC1)c(OC)cc2)C[C@H]3Cc4cccc(c4)C;
	InChI InChI=1S/C25H31NO3/c1-17-6-5-7-18(12-17)13-20-14-21(16-26-25(20)27)19-10-11-23(28-2)24(15-19)29-22-8-3-4-9-22/h5-7,10-12,15,20-22H,3-4,8-9,13-14,16H2,1-2H3,(H,26,27)/t20-,21-/m1/s1 ; Key:ABEJDMOBAFLQNJ-NHCUHLMSSA-N ;
	(verify)

HT-0712, also known as IPL-455903,^[1] is an experimental cognitive enhancing drug (nootropic) which is currently undergoing clinical trials. It is currently being licensed by Helicon Therapeutics in San Diego, California. It was originally discovered and tested as part of a preclinical anti-inflammatory program by Inflazyme Pharmaceuticals.^[2]

^ Giembycz MA (October 2008). "Can the anti-inflammatory potential of PDE4 inhibitors be realized: guarded optimism or wishful thinking?". British Journal of Pharmacology. 155 (3): 288–290. doi:10.1038/bjp.2008.297. PMC 2567889. PMID 18660832.
^ MacDonald E, Van der Lee H, Pocock D, Cole C, Thomas N, VandenBerg PM, et al. (2007). "A novel phosphodiesterase type 4 inhibitor, HT-0712, enhances rehabilitation-dependent motor recovery and cortical reorganization after focal cortical ischemia". Neurorehabilitation and Neural Repair. 21 (6): 486–496. doi:10.1177/1545968307305521. PMID 17823313.

[pmid18660832-1] Giembycz MA (October 2008). "Can the anti-inflammatory potential of PDE4 inhibitors be realized: guarded optimism or wishful thinking?". British Journal of Pharmacology. 155 (3): 288–290. doi:10.1038/bjp.2008.297. PMC 2567889. PMID 18660832.

[pmid17823313-2] MacDonald E, Van der Lee H, Pocock D, Cole C, Thomas N, VandenBerg PM, et al. (2007). "A novel phosphodiesterase type 4 inhibitor, HT-0712, enhances rehabilitation-dependent motor recovery and cortical reorganization after focal cortical ischemia". Neurorehabilitation and Neural Repair. 21 (6): 486–496. doi:10.1177/1545968307305521. PMID 17823313.

[1]

[2]